Navigation Links
UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting

YOQNEAM, Israel and SAN RAMON, California, April 3 /PRNewswire/ -- Results of an independent multi-treatment clinical study of the UltraShape(R) Contour I, the first clinically proven non-invasive solution for fat reduction and body contouring using non-thermal selective focused ultrasound will be presented at the American Society for Laser Medicine and Surgery annual meeting on April 4, 2008 in Kissimmee, Florida. The presentation is entitled "Lipotripsy: Non-invasive Ultrasonic Selective Destruction of Adipocytes using UltraShape" will take place during the scientific session The Cutting Edge in Optical Diagnostics and Therapeutics of Tissues and Cells.

Hector Leal-Silva, M.D., a dermatologic surgeon based in Monterrey, Mexico, will present the results of the 36 patient clinical study using the UltraShape system on localized fat deposits in the abdomen, flanks, and thighs. The study showed definitive, measurable results in 100 percent of patients including an average of two-inch (5cm) reduction in circumference in the abdomen after a series of three treatments, one month apart. CT scans taken in a subset of study subjects showed objective quantifiable fat thickness reduction. Photographic assessment, weight and circumferential measures were evaluated before and after each treatment and one month after the last treatment. Visual contour improvement was seen in over 85% of patients as assessed by an independent panel of physicians. Ninety-four percent (94%) of patients were satisfied with the procedure. In addition, there were no adverse events reported.

"With the major shift in patient demand toward non-invasive, pain-free, no-downtime procedures UltraShape has become a core procedure offering in my aesthetic practice," said Leal. "My clinical study demonstrated measurable circumference reduction and visual improvement in body contour in all patients. Moreover, my patients are happy with a high percentage of them returning for treatment of other body areas or recommending UltraShape to friends and family."

"Dr. Leal-Silva's impressive clinical study results combined with his successful commercial experience with UltraShape further adds to our growing body of evidence supporting UltraShape as the clinically proven non-invasive option for the reduction of localized fat deposits and improvement in body contour," said Rodger Stewart, President and Chief Executive Officer of UltraShape Inc.

About the UltraShape(R) Contour I

The UltraShape Contour I system, based on patented focused ultrasound technology, is the first scientifically and clinically proven non-invasive fat reduction and body contouring solution for both men and women. The device produces mechanical, non-thermal, acoustic effects which target and selectively destroy fat cells, leaving surrounding critical structures such as skin, blood vessels, nerves, and connective tissue intact. The UltraShape procedure is guided by proprietary real-time tracking and guidance technology designed to deliver smooth, uniform body contouring results. The software guarantees adherence to a pre-determined treatment algorithm minimizing risk of contour irregularities, a common side effect of liposuction. The UltraShape procedure is performed during a convenient, "walk-in, walk-out" session carried out in an office-based environment; it requires no anesthesia or sedation, and the vast majority of patients report no pain or discomfort. After treatment, patients immediately resume their daily routines with no need for maintenance treatments. The UltraShape procedure is available in 50 countries and over 55,000 patient treatments have been performed worldwide with high patient satisfaction. The UltraShape Contour I received the CE Mark in 2005 and a medical device license from Health Canada in 2007. The UltraShape Contour I system is not available for sale in the United States.

About UltraShape(R)

UltraShape is redefining aesthetic medicine by developing, manufacturing and marketing innovative non-invasive technologies for body contouring. The company is dedicated to providing clinically proven safe and effective solutions that enhance the lives of patients worldwide. The UltraShape proprietary non-invasive body contouring technology is based on focused ultrasound that targets and selectively disrupts fat cells without affecting surrounding structures. Founded in 2000, UltraShape is a privately held and venture backed company with offices in the United States, Israel, France, United Kingdom, and Italy. For more information visit


Abigail Marks Paula Moggio Jessica Fishman

UltraShape FischerHealth Gitam Porter Novelli

+972-4-909-9260 +1-310-577-7870 x151 +972-3-576-5798

SOURCE UltraShape Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
2. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
3. American Laser Center Offers VelaShape Body Shaping and Cellulite Reduction Treatment
4. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
5. FreshFx Recognized for use in the Scalder as a Solution to the Yield/Pathogen Reduction Dilemma
6. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
7. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
8. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
9. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
10. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
11. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
Post Your Comments:
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... Dec. 1, 2015   Craneware, Inc ., ... solutions, today announced the company will showcase a ... ® solution at the American Society ... Meeting . The new features are focused on ... monitoring and managing enterprise-wide pharmacy charges to ensure ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville ... is the only hospital in the region providing what is known as the ... pacing patients were revealed recently at a medical conference and published in The ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, “ ... a main “pain point” for merging or aligning healthcare provider organizations—when mergers and ... signed. This quick-read guidance suggests that failing to recognize the power of ...
Breaking Medicine News(10 mins):